Back to News
Market Impact: 0.35
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Source: zacks.com
Healthcare & BiotechCompany FundamentalsAnalyst InsightsTechnology & Innovation
Summit Therapeutics shares surged 17% after ivonescimab demonstrated a significant overall survival benefit versus Keytruda in a China Phase III lung cancer study. The update represents a major efficacy signal that could materially improve clinical and commercial expectations for the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
SMMT0.75
More News
- Indonesian stocks plunge to six-year low as MSCI downgrade fears mount
- Putin reportedly suggests summit with Trump and Xi to decide fate of Ukraine
- China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround
- Australia’s Cleanaway agrees to $6.5 bln EQT buyout bid; shares surge
- India’s Finance Minister blames easy exits and excess liquidity for equity market's underperformance
- Zoom and big financial firms add ‘Proof of Human’ badges from Sam Altman’s World to stop fraud and deep fakes